Telavancin
Based on 1 publication(s) in Google Scholar
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria.
It is advisable to consider the stable salt form (Telavancin hydrochloride) that retains the same biological activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 372151-71-8
- Formule: C80H106Cl2N11O27P
- Masse moléculaire:1755.63
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Other In-stock Forms of Telavancin
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Telavancin
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
Description
IC50 & Target
|
Glycopeptide |
In Vitro
Telavancin has a rapid, concentration-dependent bactericidal effect, due to disruption of cell membrane integrity[1].
Telavancin (5 μg/mL) exerts bacteriocidal effect against a MRSA strain (COL) and a VISA strain (HIP5836) at a concentration of 5 µg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MRSA bacteremia model in neutropenic mice[1]
-
Dosage:40 mg/kg
-
Administration:Subcutaneous injection; twice every day spaced 12 h apart
-
Result:Resulted a significantly higher 14-day survival compared with vancomycin-treated animals.
-
Animal Model:Rabbit model of S. aureus endocarditis[1]
-
Dosage:30 mg/kg
-
Administration:Intravenous injection; twice every day, spaced 12 h for 4 days
-
Result:Significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 372151-71-8
-
Appearance Solid
-
Masse moléculaire 1755.63
-
Formule C80H106Cl2N11O27P
-
Color White to off-white
-
SMILES
ClC1=CC([C@H]([C@](C(N[C@@H]2C(O)=O)=O)([H])N3)O)=CC=C1OC4=CC([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C3=O)([H])C(C=C6C(C2=CC(O)=C7CNC[P](O)(O)=O)=C7O)=CC=C6O)=O)=CC(OC8=CC=C([C@H]([C@H]5NC([C@H](NC)CC(C)C)=O)O)C=C8Cl)=C4O[C@H](O[C@@H]9CO)[C@@H]([C@H]([C@@H]9O)O)O[C@H](O[C@H]%10C)C[C@@](C)([C@@H]%10O)NCCNCCCCCCCCCC
-
Synonyms
TD-6424
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]2022 Dec;9(34):e2203088. PMID: 36257906
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Telavancin Related Classifications
HY-112959 Related Classifications
Powered by Bioz